Announcements Trials
Browse Landscape

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 4Observational 3

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 3Neuromyelitis Optica 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1

Interventions

Blood Specimen Collection 137Surveys and Questionnaires 131Specimen Handling 57Observation 55Radiotherapy 44Interviews as Topic 35Surgical Procedures, Operative 32Biopsy 31Drug Therapy 31Data Collection 26Magnetic Resonance Spectroscopy 25Nivolumab 21Watchful Waiting 20Immune Checkpoint Inhibitors 19Immunotherapy 17Magnetic Resonance Imaging 17Standard of Care 17Therapeutics 17palbociclib 14trastuzumab deruxtecan 14Liquid Biopsy 13Restraint, Physical 13Tomography, X-Ray Computed 13Hematologic Tests 12Radiosurgery 12Focus Groups 11Genetic Testing 11darolutamide 11enzalutamide 11pembrolizumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × ravulizumab × 1 year × Clear all
NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

NCT06967480 2026-02-05

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Recruiting
40 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚔